ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1095

A20(Tnfaip3) in Keratinocytes Restricts an Early Antiviral Gene Program Associated with Psoriatic Skin and Joint Disease

Bahram Razani1, Jared Liu1, Ryan Tobias1, Sugandh Kumar1, Zhi-Ming Huang1, Wilson Liao2, Barbara Malynn3 and Averil Ma3, 1Dept. of Dermatology, UCSF, San Francisco, 2Dept. of Dermatology, San Francisco, 3Division of Gastroenterology, UCSF, San Francisco

Meeting: ACR Convergence 2022

Keywords: Animal Model, immunology, Inflammation, Psoriatic arthritis, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: Spondyloarthritis Including PsA – Basic Science

Session Type: Abstract Session

Session Time: 10:30AM-11:30AM

Background/Purpose: A20 (Tnfaip3) levels are reduced in psoriatic plaques and polymorphisms in the TNFAIP3 gene locus are associated with increased risk for both psoriasis and psoriatic arthritis. A20 is a ubiquitin binding and editing molecule that acts as a key negative regulator of inflammatory signaling. Our prior work using knock-in mice showed that non-enzymatic A20 binding to linear ubiquitin restricted psoriatic skin and joint disease. The earliest inflammatory changes in these mice surrounded the epidermis of the distal digits. Therefore, we aimed to determine if keratinocyte A20 was critical for restricting psoriatic skin and joint disease.

Methods: We generated mice with tamoxifen inducible conditional deletion of A20 in keratinocytes (A20eKO mice) and performed detailed immunological and transcriptomic analysis of tissues and primary keratinocytes in adult mice. We also generated multiple compound mutant mice with cytokines known to play a role in psoriatic arthritis.

Results: A20eKO mice developed progressive psoriatic skin and joint disease of their distal digits with complete penetrance. Skin and joint pathology was dependent on TNF, IL17A, IL23, and T-cells, reflecting factors known to play a role in human psoriatic disease. The earliest in vivo transcriptomic changes following A20 deletion in keratinocytes demonstrated a profound antiviral gene program. Intriguingly, deletion of A20 in primary keratinocytes in vitro resulted in spontaneous activation of antiviral genes, dependent the presence of Sting (Tmem173).

Conclusion: A20 in keratinocytes restricts not only psoriatic skin disease, but also psoriatic joint disease, suggesting an important role for epidermal immune homeostasis in preventing arthritis. Skin and joint pathology is dependent on TNF, IL17A, IL23, and T-cells, demonstrating the importance of epidermal A20 in restricting psoriatic cytokine and cellular networks. Intriguingly, the earliest transcriptomic changes following epidermal A20 loss in vivo is an antiviral gene program. This is reflected by primary keratinocytes in culture, suggesting a cell autonomous role for A20 in restricting antiviral genes. Furthermore, spontaneous induction of antiviral genes in primary keratinocytes in vitro was Sting (Tmem173) dependent. Given the known presence of antiviral genes in human psoriatic plaques, these studies raise the possibility that A20 prevents psoriatic skin and joint pathology in part by restricting a Sting-dependent antiviral gene program in keratinocytes.


Disclosures: B. Razani, None; J. Liu, Novartis, Janssen, TrexBio, Amgen; R. Tobias, None; S. Kumar, None; Z. Huang, None; W. Liao, AbbVie/Abbott, Janssen, Novartis, Pfizer, TRex Bio, Regeneron, Leo Pharma; B. Malynn, None; A. Ma, None.

To cite this abstract in AMA style:

Razani B, Liu J, Tobias R, Kumar S, Huang Z, Liao W, Malynn B, Ma A. A20(Tnfaip3) in Keratinocytes Restricts an Early Antiviral Gene Program Associated with Psoriatic Skin and Joint Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a20tnfaip3-in-keratinocytes-restricts-an-early-antiviral-gene-program-associated-with-psoriatic-skin-and-joint-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a20tnfaip3-in-keratinocytes-restricts-an-early-antiviral-gene-program-associated-with-psoriatic-skin-and-joint-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology